Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the completion of the sale, the insider now owns 5,875,851 shares of the company's stock, valued at approximately $8,343,708.42. The trade was a 36.65 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Aldeyra Therapeutics Stock Performance
ALDX stock opened at $1.95 on Tuesday. Aldeyra Therapeutics, Inc has a 1 year low of $1.14 and a 1 year high of $7.20. The company has a fifty day simple moving average of $5.94 and a 200 day simple moving average of $5.42. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18.
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.30). As a group, research analysts expect that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.
Hedge Funds Weigh In On Aldeyra Therapeutics
A number of institutional investors have recently modified their holdings of ALDX. Hsbc Holdings PLC bought a new stake in shares of Aldeyra Therapeutics during the 4th quarter worth $52,000. Balyasny Asset Management L.P. acquired a new position in Aldeyra Therapeutics during the 4th quarter worth $56,000. Paloma Partners Management Co bought a new stake in Aldeyra Therapeutics during the third quarter valued at about $62,000. Catalyst Funds Management Pty Ltd grew its position in shares of Aldeyra Therapeutics by 2,083.3% in the fourth quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company's stock valued at $65,000 after purchasing an additional 12,500 shares during the last quarter. Finally, Regal Investment Advisors LLC bought a new position in shares of Aldeyra Therapeutics in the fourth quarter worth about $66,000. Institutional investors own 59.71% of the company's stock.
Analysts Set New Price Targets
Several analysts recently issued reports on the company. BTIG Research cut their price objective on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a report on Monday. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Friday.
View Our Latest Report on ALDX
About Aldeyra Therapeutics
(
Get Free Report)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
